
Pancreatic Cancer Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030
Description
Pancreatic Cancer Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030
The report on the global pancreatic cancer market provides qualitative and quantitative analysis for the period from 2021-2030. The global pancreatic cancer market was valued at USD 2448.9 million in 2022 and is expected treach USD 7114.4 million in 2030, with a CAGR of 12.5% during the forecast period 2023-2030. The study on pancreatic cancer market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.
Rising rates of pancreatic cancer cases and frequency drive the market for pancreatic cancer market. As per the WCRF International, “it is stated that pancreatic cancer is the 12th most common cancer worldwide. Pancreatic cancer is majorly caused due tobesity, diabetes, and extremely tall height. For instance, The International Diabetes Foundation estimates that there are 537 million people (20-79 years old) whhave diabetes worldwide. There will be 643 million diabetics globally by 2030, and there will be 783 million by 2045. Another factor fueling the demand for the pancreatic cancer market is rising government initiatives and improving healthcare infrastructure. Companies are collaborating with the government and other public organizations tcure pancreatic cancer. For instance, Servier announced today, in collaboration with the International Society for Clinical Oncology (ISCO) and the Egyptian Foundation for Medical Sciences (EFMS), the launch of its treatment for pancreatic cancer in Egypt.
The global pancreatic cancer market is bifurcated by type, treatment type, diagnosis route of administration, and distribution channel. By type, the segment is further bifurcated intexocrine and endocrine. The exocrine segment is anticipated tgrow at a faster rate than the market growth during the forecast period. Exocrine pancreatic cancer develops from exocrine cells, which make up the exocrine gland and ducts of the pancreas. Tcure Exocrine Pancreatic Cancer surgery is conducted tremove the tumor, relieve the symptoms, or prevent complications. Radiation treatments, which use X-rays tkill cancer cells. Chemotherapy is alssuggested with chemicals or drugs. Immunotherapy or biological therapy is alsan effective treatment. According tan article published on pancreatic adenocarcinoma, 90 % of pancreatic cancer is arising in the exocrine glands of the pancreas, and pancreatic neuroendocrine tumor which is less common occurs in the endocrine tissue of the pancreas.
The global pancreatic cancer market is segmented intthe Asia Pacific, North America, Europe, the Middle East & Africa, and South America. North America is predicted tbe the fastest-growing region within the global market share. The U.S. is expected thold onta sizable market share due tits high expenditures on healthcare, compassionate reimbursement procedures, and rising pancreatic cancer occurrence. According tthe National Program of Cancer Registries database,” encompassing almost 65% of the U.S. population, indicates that the incidence of pancreatic cancer is rising faster in people under the age of 55 than in people beyond the age of 55, and more quickly in women than in males. “For instance, The Advanced Research Projects Agency for Health (ARPA-H) has President Biden's bold new vision for biomedical and health research. The objective of this organization is tincrease the capacity of the American government texpedite research that can enhance human health and tincrease our capacity tprevent, detect, and treat a variety of diseases, including pancreatic cancer.
Report Findings
1) Drivers
Rising rates of pancreatic cancer cases and frequency drive the market for pancreatic cancer market.
Rising government initiatives and improving healthcare infrastructure fuels the market for pancreatic cancer treatment.
2) Restraints
High cost and side effects associated with treatment are likely thamper the pancreatic cancer market growth.
3) Opportunities
Advancements in diagnostic technology and the development of drugs fuels the pancreatic cancer market.
Research Methodology
A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from the industry
Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.
The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global pancreatic cancer market is segmented on the basis of type, treatment type, diagnosis, route of administration, end user, and distribution channel.
The Global Pancreatic Cancer Market by Type
Exocrine
Endocrine
The Global Pancreatic Cancer Market by Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Others
The Global Pancreatic Cancer Market by Diagnosis
Blood Test
Biopsy
Imaging Tests
Ultrasound
Computerized Tomography (CT) scans
Others
The Global Pancreatic Cancer Market by Route of Administration
Oral
Parenteral
Others
The Global Pancreatic Cancer Market by End User
Hospitals
Specialty Clinics
Homecare
Others
The Global Pancreatic Cancer Market by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Company Profiles
The companies covered in the report include
Bayer AG
Mylan (is now part of Viatris)
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
GSK plc
Novartis AG
Zydus Lifesciences Ltd.
AstraZeneca
Johnson & Johnson Services, Inc.
What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the pancreatic cancer market.
2. Complete coverage of all the segments in the pancreatic cancer market tanalyze the trends, developments in the global market and forecast of market size up t2030.
3. Comprehensive analysis of the companies operating in the global pancreatic cancer market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus tinvest, consolidate, expand and/or diversify.
Table of Contents
400 Pages
- Chapter 1. Preface
- 1.1. Report Description
- 1.2. Research Methods
- 1.3. Research Approaches
- Chapter 2. Executive Summary
- 2.1. Pancreatic Cancer Market Highlights
- 2.2. Pancreatic Cancer Market Projection
- 2.3. Pancreatic Cancer Market Regional Highlights
- Chapter 3. Global Pancreatic Cancer Market Overview
- 3.1. Introduction
- 3.2. Market Dynamics
- 3.2.1. Drivers
- 3.2.2. Restraints
- 3.2.3. Opportunities
- 3.3. Porter's Five Forces Analysis
- 3.4. IGR-Growth Matrix Analysis
- 3.4.1. IGR-Growth Matrix Analysis by Type
- 3.4.2. IGR-Growth Matrix Analysis by Treatment Type
- 3.4.3. IGR-Growth Matrix Analysis by Diagnosis
- 3.4.4. IGR-Growth Matrix Analysis by Route Of Administration
- 3.4.5. IGR-Growth Matrix Analysis by End User
- 3.4.6. IGR-Growth Matrix Analysis by Distribution Channel
- 3.4.7. IGR-Growth Matrix Analysis by Region
- 3.5. Value Chain Analysis of Pancreatic Cancer Market
- Chapter 4. Pancreatic Cancer Market Macro Indicator Analysis
- Chapter 5. Company Profiles and Competitive Landscape
- 5.1. Competitive Landscape in the Global Pancreatic Cancer Market
- 5.2. Companies Profiles
- 5.2.1. Bayer AG
- 5.2.2. Mylan (is now part of Viatris)
- 5.2.3. Teva Pharmaceutical Industries Ltd.
- 5.2.4. Sanofi
- 5.2.5. Pfizer Inc.
- 5.2.6. GSK plc
- 5.2.7. Novartis AG
- 5.2.8. Zydus Lifesciences Ltd.
- 5.2.9. AstraZeneca
- 5.2.10. Johnson & Johnson Services, Inc.
- Chapter 6. Global Pancreatic Cancer Market by Type
- 6.1. Exocrine
- 6.2. Endocrine
- Chapter 7. Global Pancreatic Cancer Market by Treatment Type
- 7.1. Chemotherapy
- 7.2. Targeted Therapy
- 7.3. Immunotherapy
- 7.4. Hormone Therapy
- 7.5. Others
- Chapter 8. Global Pancreatic Cancer Market by Diagnosis
- 8.1. Blood Test
- 8.2. Biopsy
- 8.3. Imaging Tests
- 8.4. Ultrasound
- 8.5. Computerized Tomography (CT) scans
- 8.6. Others
- Chapter 9. Global Pancreatic Cancer Market by Route of Administration
- 9.1. Oral
- 9.2. Parenteral
- 9.3. Others
- Chapter 10. Global Pancreatic Cancer Market by End User
- 10.1. Hospitals
- 10.2. Specialty Clinics
- 10.3. Homecare
- 10.4. Others
- Chapter 11. Global Pancreatic Cancer Market by Distribution Channel
- 11.1. Hospital Pharmacy
- 11.2. Retail Pharmacy
- 11.3. Online Pharmacy
- 11.4. Others
- Chapter 12. Global Pancreatic Cancer Market by Region 2023-2030
- 12.1. North America
- 12.1.1. North America Pancreatic Cancer Market by Type
- 12.1.2. North America Pancreatic Cancer Market by Treatment Type
- 12.1.3. North America Pancreatic Cancer Market by Diagnosis
- 12.1.4. North America Pancreatic Cancer Market by Route of Administration
- 12.1.5. North America Pancreatic Cancer Market by End User
- 12.1.6. North America Pancreatic Cancer Market by Distribution Channel
- 12.1.7. North America Pancreatic Cancer Market by Country
- 12.1.7.1. The U.S. Pancreatic Cancer Market
- 12.1.7.1.1. The U.S. Pancreatic Cancer Market by Type
- 12.1.7.1.2. The U.S. Pancreatic Cancer Market by Treatment Type
- 12.1.7.1.3. The U.S. Pancreatic Cancer Market by Diagnosis
- 12.1.7.1.4. The U.S. Pancreatic Cancer Market by Route of Administration
- 12.1.7.1.5. The U.S. Pancreatic Cancer Market by End User
- 12.1.7.1.6. The U.S. Pancreatic Cancer Market by Distribution Channel
- 12.1.7.2. Canada Pancreatic Cancer Market
- 12.1.7.2.1. Canada Pancreatic Cancer Market by Type
- 12.1.7.2.2. Canada Pancreatic Cancer Market by Treatment Type
- 12.1.7.2.3. Canada Pancreatic Cancer Market by Diagnosis
- 12.1.7.2.4. Canada Pancreatic Cancer Market by Route of Administration
- 12.1.7.2.5. Canada Pancreatic Cancer Market by End User
- 12.1.7.2.6. Canada Pancreatic Cancer Market by Distribution Channel
- 12.1.7.3. Mexico Pancreatic Cancer Market
- 12.1.7.3.1. Mexico Pancreatic Cancer Market by Type
- 12.1.7.3.2. Mexico Pancreatic Cancer Market by Treatment Type
- 12.1.7.3.3. Mexico Pancreatic Cancer Market by Diagnosis
- 12.1.7.3.4. Mexico Pancreatic Cancer Market by Route of Administration
- 12.1.7.3.5. Mexico Pancreatic Cancer Market by End User
- 12.1.7.3.6. Mexico Pancreatic Cancer Market by Distribution Channel
- 12.2. Europe
- 12.2.1. Europe Pancreatic Cancer Market by Type
- 12.2.2. Europe Pancreatic Cancer Market by Treatment Type
- 12.2.3. Europe Pancreatic Cancer Market by Diagnosis
- 12.2.4. Europe Pancreatic Cancer Market by Route of Administration
- 12.2.5. Europe Pancreatic Cancer Market by End User
- 12.2.6. Europe Pancreatic Cancer Market by Distribution Channel
- 12.2.7. Europe Pancreatic Cancer Market by Country
- 12.2.7.1. Germany Pancreatic Cancer Market
- 12.2.7.1.1. Germany Pancreatic Cancer Market by Type
- 12.2.7.1.2. Germany Pancreatic Cancer Market by Treatment Type
- 12.2.7.1.3. Germany Pancreatic Cancer Market by Diagnosis
- 12.2.7.1.4. Germany Pancreatic Cancer Market by Route of Administration
- 12.2.7.1.5. Germany Pancreatic Cancer Market by End User
- 12.2.7.1.6. Germany Pancreatic Cancer Market by Distribution Channel
- 12.2.7.2. United Kingdom Pancreatic Cancer Market
- 12.2.7.2.1. United Kingdom Pancreatic Cancer Market by Type
- 12.2.7.2.2. United Kingdom Pancreatic Cancer Market by Treatment Type
- 12.2.7.2.3. United Kingdom Pancreatic Cancer Market by Diagnosis
- 12.2.7.2.4. United Kingdom Pancreatic Cancer Market by Route of Administration
- 12.2.7.2.5. United Kingdom Pancreatic Cancer Market by End User
- 12.2.7.2.6. United Kingdom Pancreatic Cancer Market by Distribution Channel
- 12.2.7.3. France Pancreatic Cancer Market
- 12.2.7.3.1. France Pancreatic Cancer Market by Type
- 12.2.7.3.2. France Pancreatic Cancer Market by Treatment Type
- 12.2.7.3.3. France Pancreatic Cancer Market by Diagnosis
- 12.2.7.3.4. France Pancreatic Cancer Market by Route of Administration
- 12.2.7.3.5. France Pancreatic Cancer Market by End User
- 12.2.7.3.6. France Pancreatic Cancer Market by Distribution Channel
- 12.2.7.4. Italy Pancreatic Cancer Market
- 12.2.7.4.1. Italy Pancreatic Cancer Market by Type
- 12.2.7.4.2. Italy Pancreatic Cancer Market by Treatment Type
- 12.2.7.4.3. Italy Pancreatic Cancer Market by Diagnosis
- 12.2.7.4.4. Italy Pancreatic Cancer Market by Route of Administration
- 12.2.7.4.5. Italy Pancreatic Cancer Market by End User
- 12.2.7.4.6. Italy Pancreatic Cancer Market by Distribution Channel
- 12.2.7.5. Rest of Europe Pancreatic Cancer Market
- 12.2.7.5.1. Rest of Europe Pancreatic Cancer Market by Type
- 12.2.7.5.2. Rest of Europe Pancreatic Cancer Market by Treatment Type
- 12.2.7.5.3. Rest of Europe Pancreatic Cancer Market by Diagnosis
- 12.2.7.5.4. Rest of Europe Pancreatic Cancer Market by Route of Administration
- 12.2.7.5.5. Rest of Europe Pancreatic Cancer Market by End User
- 12.2.7.5.6. Rest of Europe Pancreatic Cancer Market by Distribution Channel
- 12.3. Asia Pacific
- 12.3.1. Asia Pacific Pancreatic Cancer Market by Type
- 12.3.2. Asia Pacific Pancreatic Cancer Market by Treatment Type
- 12.3.3. Asia Pacific Pancreatic Cancer Market by Diagnosis
- 12.3.4. Asia Pacific Pancreatic Cancer Market by Route of Administration
- 12.3.5. Asia Pacific Pancreatic Cancer Market by End User
- 12.3.6. Asia Pacific Pancreatic Cancer Market by Distribution Channel
- 12.3.7. Asia Pacific Pancreatic Cancer Market by Country
- 12.3.7.1. China Pancreatic Cancer Market
- 12.3.7.1.1. China Pancreatic Cancer Market by Type
- 12.3.7.1.2. China Pancreatic Cancer Market by Treatment Type
- 12.3.7.1.3. China Pancreatic Cancer Market by Diagnosis
- 12.3.7.1.4. China Pancreatic Cancer Market by Route of Administration
- 12.3.7.1.5. China Pancreatic Cancer Market by End User
- 12.3.7.1.6. China Pancreatic Cancer Market by Distribution Channel
- 12.3.7.2. Japan Pancreatic Cancer Market
- 12.3.7.2.1. Japan Pancreatic Cancer Market by Type
- 12.3.7.2.2. Japan Pancreatic Cancer Market by Treatment Type
- 12.3.7.2.3. Japan Pancreatic Cancer Market by Diagnosis
- 12.3.7.2.4. Japan Pancreatic Cancer Market by Route of Administration
- 12.3.7.2.5. Japan Pancreatic Cancer Market by End User
- 12.3.7.2.6. Japan Pancreatic Cancer Market by Distribution Channel
- 12.3.7.3. India Pancreatic Cancer Market
- 12.3.7.3.1. India Pancreatic Cancer Market by Type
- 12.3.7.3.2. India Pancreatic Cancer Market by Treatment Type
- 12.3.7.3.3. India Pancreatic Cancer Market by Diagnosis
- 12.3.7.3.4. India Pancreatic Cancer Market by Route of Administration
- 12.3.7.3.5. India Pancreatic Cancer Market by End User
- 12.3.7.3.6. India Pancreatic Cancer Market by Distribution Channel
- 12.3.7.4. South Korea Pancreatic Cancer Market
- 12.3.7.4.1. South Korea Pancreatic Cancer Market by Type
- 12.3.7.4.2. South Korea Pancreatic Cancer Market by Treatment Type
- 12.3.7.4.3. South Korea Pancreatic Cancer Market by Diagnosis
- 12.3.7.4.4. South Korea Pancreatic Cancer Market by Route of Administration
- 12.3.7.4.5. South Korea Pancreatic Cancer Market by End User
- 12.3.7.4.6. South Korea Pancreatic Cancer Market by Distribution Channel
- 12.3.7.5. Australia Pancreatic Cancer Market
- 12.3.7.5.1. Australia Pancreatic Cancer Market by Type
- 12.3.7.5.2. Australia Pancreatic Cancer Market by Treatment Type
- 12.3.7.5.3. Australia Pancreatic Cancer Market by Diagnosis
- 12.3.7.5.4. Australia Pancreatic Cancer Market by Route of Administration
- 12.3.7.5.5. Australia Pancreatic Cancer Market by End User
- 12.3.7.5.6. Australia Pancreatic Cancer Market by Distribution Channel
- 12.3.7.6. Rest of Asia-Pacific Pancreatic Cancer Market
- 12.3.7.6.1. Rest of Asia-Pacific Pancreatic Cancer Market by Type
- 12.3.7.6.2. Rest of Asia-Pacific Pancreatic Cancer Market by Treatment Type
- 12.3.7.6.3. Rest of Asia-Pacific Pancreatic Cancer Market by Diagnosis
- 12.3.7.6.4. Rest of Asia-Pacific Pancreatic Cancer Market by Route of Administration
- 12.3.7.6.5. Rest of Asia-Pacific Pancreatic Cancer Market by End User
- 12.3.7.6.6. Rest of Asia-Pacific Pancreatic Cancer Market by Distribution Channel
- 12.4. RoW
- 12.4.1. RoW Pancreatic Cancer Market by Type
- 12.4.2. RoW Pancreatic Cancer Market by Treatment Type
- 12.4.3. RoW Pancreatic Cancer Market by Diagnosis
- 12.4.4. RoW Pancreatic Cancer Market by Route of Administration
- 12.4.5. RoW Pancreatic Cancer Market by End User
- 12.4.6. RoW Pancreatic Cancer Market by Distribution Channel
- 12.4.7. RoW Pancreatic Cancer Market by Sub-region
- 12.4.7.1. Latin America Pancreatic Cancer Market
- 12.4.7.1.1. Latin America Pancreatic Cancer Market by Type
- 12.4.7.1.2. Latin America Pancreatic Cancer Market by Treatment Type
- 12.4.7.1.3. Latin America Pancreatic Cancer Market by Diagnosis
- 12.4.7.1.4. Latin America Pancreatic Cancer Market by Route of Administration
- 12.4.7.1.5. Latin America Pancreatic Cancer Market by End User
- 12.4.7.1.6. Latin America Pancreatic Cancer Market by Distribution Channel
- 12.4.7.2. Middle East Pancreatic Cancer Market
- 12.4.7.2.1. Middle East Pancreatic Cancer Market by Type
- 12.4.7.2.2. Middle East Pancreatic Cancer Market by Treatment Type
- 12.4.7.2.3. Middle East Pancreatic Cancer Market by Diagnosis
- 12.4.7.2.4. Middle East Pancreatic Cancer Market by Route of Administration
- 12.4.7.2.5. Middle East Pancreatic Cancer Market by End User
- 12.4.7.2.6. Middle East Pancreatic Cancer Market by Distribution Channel
- 12.4.7.3. Africa Pancreatic Cancer Market
- 12.4.7.3.1. Africa Pancreatic Cancer Market by Type
- 12.4.7.3.2. Africa Pancreatic Cancer Market by Treatment Type
- 12.4.7.3.3. Africa Pancreatic Cancer Market by Diagnosis
- 12.4.7.3.4. Africa Pancreatic Cancer Market by Route of Administration
- 12.4.7.3.5. Africa Pancreatic Cancer Market by End User
- 12.4.7.3.6. Africa Pancreatic Cancer Market by Distribution Channel
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.